natgillin/translations-raw huggingface dataset:
The active substance in Joicela, lumiracoxib, is a selective ‘non-steroidal anti-inflammatory drug' (NSAID) that belongs to the group ‘cyclo-oxygenase 2 (COX-2) inhibitors'.
Zdravilna učinkovina v zdravilu Joicela, lumirakoksib, je selektivno „nesteroidno protivnetno zdravilo“ (NSAID), ki spada v skupino „zaviralcev ciklooksigenaze 2 (COX-2)”.
On 15 April 2011, Novartis officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Joicela for the symptomatic relief in the treatment of osteoarthritis of the knee and hip in patients who are not carriers of the DQA1*0102 allele.
Družba Novartis je dne 15. aprila 2011 uradno obvestila Odbor za zdravila za uporabo v humani medicini (CHMP), da želi umakniti vlogo za pridobitev dovoljenja za promet z zdravilom Joicela, namenjenim lajšanju simptomov pri zdravljenju osteoartritisa kolena in kolka pri bolnikih, ki niso prenašalci alela DQA1*0102.
Based on the review of the data and the company's response to the CHMP's lists of questions, the CHMP had some concerns and was of the provisional opinion that Joicela could not have been approved for the symptomatic treatment of osteoarthritis (swelling and pain in the joints) of the knee and hip in adults who are not carriers of DQA1*0102.
Na podlagi pregleda podatkov in odgovorov družbe na sezname vprašanj, ki jih je zastavil CHMP, je Odbor izrazil določene zadržke in je začasno menil, da zdravila Joicela ni mogoče odobriti za simptomatsko zdravljenje osteoartritisa (zatekanje in bolečine v sklepih) kolena in kolka pri odraslih, ki niso prenašalci DQA1*0102.
Joicela was compared with celecoxib (another medicine used in osteoarthritis) and placebo (a dummy treatment) in three main studies.
Zdravilo Joicela so v treh glavnih študijah primerjali s celekoksibom (drugim zdravilom, ki se uporablja pri osteoartritisu) in placebom (zdravilom brez zdravilne učinkovine).
How is Joicela expected to work?
Kako naj bi zdravilo Joicela delovalo?
Joicela is a medicine that contains the active substance lumiracoxib.
Joicela je zdravilo, ki vsebuje zdravilno učinkovino lumirakoksib.
Joicela was expected to be used to relieve the symptoms of osteoarthritis (swelling and pain in the joints) of the knee and hip in adults who are not carriers of a gene variant called ‘DQA1*0102'.
Zdravilo Joicela naj bi lajšalo simptome osteoartritisa (zatekanje in bolečine v sklepih) kolena in kolka pri odraslih, ki niso prenašalci genske različice, imenovane „DQA1*0102“.
What was Joicela expected to be used for?
Za kaj naj bi se zdravilo Joicela uporabljalo?
Withdrawal of the marketing authorisation application for Joicela (lumiracoxib) EMA/917506/2011
EMA/917504/2011
Background information
OSNOVNE INFORMACIJE
27 January 2010
27. januarja 2010
The final opinion was converted into a Decision by the European Commission on 27 January 2010.
Končno mnenje je bilo spremenjeno v odločbo Evropske komisije dne 27. januarja 2010.
The application was submitted in the framework of Article 32 of Directive 2001/82/EC, as amended, where the Reference Member State was Slovakia and the Concerned Member States were Poland and Spain.
Vloga je bila predložena v okviru člena 32 Direktive 2001/82/ES, kakor je bila spremenjena, pri čemer je bila referenčna država članica Slovaška, zadevni državi članici pa Poljska in Španija.
Due to concerns raised by Spain during the Mutual Recognition Procedure that APPM Respipharm may pose a potentially serious risk to human or animal health or to the environment with respect to quality and efficacy of the product, the Reference Member State, Slovakia, referred the matter to the Agency on 7 October 2008 under Article 33(4) of Directive 2001/82/EC.
Zaradi zadržkov, ki jih je v postopku z medsebojnim priznavanjem izrazila Španija, in sicer, da utegne zdravilo APPM Respipharm predstavljati resno tveganje za zdravje ljudi ali živali oziroma za okolje z vidika kakovosti in učinkovitosti zdravila, je referenčna država članica Slovaška v skladu s členom 33(4) Direktive 2001/82/ES dne 7. oktobra 2008 zadevo napotila na Agencijo .
The Mutual Recognition Procedure started on 3 April 2008.
Postopek z medsebojnim priznavanjem se je začel dne 3. aprila 2008.
Written explanations were provided by the Marketing Authorisation Holder on 14 January 2009 and supplementary information was submitted on 22 April 2009.
Imetnik dovoljenja za promet z zdravilom je dne 14. januarja 2009 podal razlago v pisni obliki, dodatne informacije pa je predložil dne 22. aprila
The Committee appointed Dr Anna-Maria Brady as rapporteur and Dr Frédéric Descamps as co-rapporteur.
Odbor je za poročevalko imenoval dr. AnnoMario Brady, za soporočevalca pa dr. Frédérica Descampsa.
Based on the evaluation of the rapporteur's assessment of the currently available data, the CVMP considered that the application does not satisfy the criteria for authorisation in respect of efficacy.
Na podlagi vrednotenja poročevalkine ocene trenutno razpoložljivih podatkov je CVMP menil, da vloga ne izpolnjuje merila za odobritev z vidika učinkovitosti.
APPM Respipharm is a multi-component formaldehyde inactivated whole-cell bacterial vaccine containing three strains of Actinobacillus pleuropneumoniae (Serotypes 2, 9 and 11) and one strain of Pasteurella multocida (Serotype A).
Zdravilo APPM Respipharm je večkomponentno, s formaldehidom inaktivirano bakterijsko cepivo s celimi celicami, ki vsebuje tri seve bakterije Actinobacillus pleuropneumoniae (serotipe 2, 9 in 11) in en sev bakterije Pasteurella multocida (serotip A).
on 14 September 2009.
predložila dne 14. septembra 2009.
notified the Agency of its intention to request the reexamination of the CVMP opinion of 15 July 2009.
je dne 28. julija 2009 je Agencijo obvestila o svoji nameri, da bo zahtevala ponovni pregled mnenja CVMP z dne 15. julija 2009.
During its 15-17 September 2009 meeting, the CVMP appointed Dr Kristina Lehmann as rapporteur and Prof. Tibor Soós as co-rapporteur for the re-examination of the abovementioned opinion.
Na zasedanju od 15. do 17. septembra 2009 je CVMP za poročevalko pri ponovnem pregledu zgoraj navedenega mnenja imenoval dr. Kristino Lehmann, za soporočevalca pa prof. Tiborja Soósa.
The product is indicated for use in pigs (sows and weaned piglets) from 6 weeks of age, intended to induce active immunisation of sows and piglets against pleuropneumonia caused by Actinobacillus pleuropneumoniae and against secondary infection by Pasteurella multocida.
Zdravilo je indicirano za uporabo pri prašičih (svinjah in odstavljenih prašičkih) od 6. tedna starosti za sprožitev aktivne imunizacije svinj in prašičkov proti plevropnevmoniji, ki jo povzroča bakterija Actinobacillus pleuropneumoniae, ter proti sekundarni okužbi z bakterijo Pasteurella multocida.
The re-examination procedure started on 15 September 2009.
Postopek ponovnega pregleda se je začel dne 15. septembra 2009.
Opinion following an Article 33(4) referral for APPM Respipharm EMA/839689/2009
Mnenje v zvezi z napotitvijo v skladu s členom 33(4) za zdravilo APPM Respipharm EMA/66751/2010
Therefore, the Committee adopted an opinion on 15 July 2009 recommending the suspension of the existing Marketing Authorisation and the refusal of the granting of the Marketing Authorisations for APPM Respipharm.
Odbor je zato dne 15. julija 2009 sprejel mnenje, v katerem je priporočil umik obstoječega dovoljenja za promet in zavrnitev odobritve dovoljenj za promet z zdravilom APPM Respipharm.
The referral procedure started on 15 October 2008.
Napotitveni postopek se je začel dne 15. oktobra 2008.
The Marketing Authorisation Holder, Pharmagal Bio s.r.o., submitted an application via mutual recognition for APPM Respipharm, on the basis of the marketing authorisation granted by Slovakia.
Imetnik dovoljenja za promet z zdravilom, družba Pharmagal Bio s.r.o., je predložil vlogo po postopku z medsebojnim priznavanjem za zdravilo APPM Respipharm na podlagi dovoljenja za promet, ki ga je odobrila Slovaška.
Based on the evaluation of the rapporteur's assessment of the currently available data, the CVMP considered that its opinion of 15 July 2009 should not be revised, and therefore adopted an opinion on 11 November 2009 recommending the suspension of the existing Marketing Authorisation and the refusal of the granting of the Marketing Authorisations for APPM Respipharm.
Na podlagi vrednotenja poročevalkine ocene trenutno razpoložljivih podatkov je CVMP menil, da svojega mnenja z dne 15. julija 2009 ni treba popraviti, zato je dne 11. novembra 2009 sprejel mnenje, v katerem je priporočil umik obstoječega dovoljenja za promet in zavrnitev odobritve dovoljenj za promet z zdravilom APPM Respipharm.
The detailed grounds for the re-examination were submitted by Pharmagal Bio s.r.o.
Podrobno utemeljitev zahtevka za ponovni pregled je družba Pharmagal Bio s.r.o.
On 28 July 2009, Pharmagal Bio s.r.o.
Družba Pharmagal Bio s.r.o.
Opinion following an Article 33(4)
Mnenje v zvezi z napotitvijo v skladu s členom 33(4)1 za zdravilo APPM Respipharm
Pioglitazone ratio, pioglitazone, makes cells (fat, muscle and liver) more sensitive to insulin, which means that the body makes better use of the insulin it produces.
učinkovina zdravila Pioglitazone ratio, pioglitazon, poveča občutljivost celic (maščevja, mišic in jeter) za insulin, kar pomeni, da telo bolje izrablja insulin, ki ga proizvaja.
This means that Pioglitazone ratio is similar to a ‘reference medicine' already authorised in the European Union (EU) called Actos.
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Actos.
Pioglitazone ratio was to be used to treat type 2 diabetes in adults, particularly those who are overweight.
Zdravilo Pioglitazone ratio naj bi se uporabljalo za zdravljenje sladkorne bolezni tipa 2 pri odraslih, zlasti tistih s prekomerno telesno maso.
On 3 February 2012, ratiopharm GmbH officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Pioglitazone ratio, for the treatment of type 2 diabetes.
Družba ratiopharm GmbH je dne 3. februarja 2012 uradno obvestila Odbor za zdravila za uporabo v humani medicini (CHMP), da želi umakniti vlogo za pridobitev dovoljenja za promet z zdravilom Pioglitazone ratio, namenjenim zdravljenju sladkorne bolezni tipa 2.
Because Pioglitazone ratio is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Actos.
Ker je zdravilo Pioglitazone ratio generično zdravilo, so bile študije pri bolnikih omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Actos.
Pioglitazone ratio was developed as a ‘generic medicine'.
Zdravilo Pioglitazone ratio je bilo razvito kot „generično zdravilo“.
Therefore, at the time of the withdrawal, the CHMP had given a positive opinion, recommending that a marketing authorisation be granted for Pioglitazone ratio for the treatment of type 2 diabetes.
Odbor je zato v času umika vloge izrazil pozitivno mnenje in priporočil odobritev vloge za pridobitev dovoljenja za promet z zdravilom Pioglitazone ratio za zdravljenje sladkorne bolezni tipa 2.
Pioglitazone ratio is a medicine that contains the active substance pioglitazone.
Pioglitazone ratio je zdravilo, ki vsebuje zdravilno učinkovino pioglitazon.
The CHMP concluded that, in accordance with EU requirements, Pioglitazone ratio had been shown to have comparable quality and to be bioequivalent to Actos.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Pioglitazone ratio primerljivo raven kakovosti kot zdravilo Actos ter da mu je biološko enakovredno.
Pioglitazone ratio was to be used on its own in patients for whom metformin (another antidiabetes medicine) is not suitable.
Prav tako naj bi se uporabljalo samostojno pri bolnikih, za katere metformin (drugo zdravilo proti sladkorni bolezni) ni primeren.
Pioglitazone ratio was also to be used together with insulin in patients who are not satisfactorily controlled with insulin alone and cannot take metformin.
Uporabljalo naj bi se tudi skupaj z insulinom pri bolnikih, pri katerih bolezen ni zadostno nadzorovana z insulinom samim in za katere metformin ni primeren.
What is Pioglitazone ratio?
Kaj je zdravilo Pioglitazone ratio?
How is Pioglitazone ratio expected to work?
Kako naj bi zdravilo Pioglitazone ratio delovalo?
What was Pioglitazone ratio expected to be used for?
Za kaj naj bi se zdravilo Pioglitazone ratio uporabljalo?
The active substance in
Zdravilna
The European Commission granted a marketing authorisation valid throughout the European Union for Zyclara on 23 August 2012.
Evropska komisija je dovoljenje za promet z zdravilom Zyclara, veljavno po vsej Evropski uniji, izdala 23. avgusta 2012.
What measures are being taken to ensure the safe and effective use of Zyclara?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Zyclara?
The full EPAR for Zyclara can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Zyclara je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
In addition, its lower strength allows it to be used across larger areas of the skin and thereby treat more of the affected skin.
Poleg tega njegova manjša jakost omogoča, da se uporablja na večjih predelih kože, kar omogoča zdravljenje večjih površin prizadete kože.
Some other side effects, including headache and tiredness, were also reported.
Poročali so tudi o nekaj drugih neželenih učinkih, vključno z glavobolom in utrujenostjo.
This means that it is similar to a ‘reference medicine' containing the same active substance, but Zyclara is available in a different strength.
To pomeni, da je podobno referenčnemu zdravilu, ki vsebuje enako zdravilno učinkovino, vendar je zdravilo Zyclara na voljo z drugačno jakostjo.
If actinic keratosis does not improve enough with Zyclara, a different treatment should be tried.
Če se aktinična keratoza z zdravilom Zyclara ne izboljša dovolj, je treba poskusiti z drugačnim zdravljenjem.
Other information about Zyclara
Druge informacije o zdravilu Zyclara
What benefits of Zyclara have been shown in studies?
Kakšne koristi je zdravilo Zyclara izkazalo v študijah?
When imiquimod is applied to the skin, it acts locally on the immune system to trigger the release of cytokines, including interferon.
Ko se imikvimod nanese na kožo, deluje lokalno na imunski sistem, da spodbudi sproščanje citokinov, vključno z interferonom.
This is followed by a 2-week break without treatment and then a further 2 weeks of treatment.
Temu sledita dva tedna premora brez zdravljenja in nato dodatno dvotedensko zdravljenje.
This is a summary of the European public assessment report (EPAR) for Zyclara.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Zyclara.
Zyclara is a ‘hybrid medicine'.
Zdravilo Zyclara je „hibridno zdravilo“.
What is Zyclara and what is it used for?
Kaj je zdravilo Zyclara in za kaj se uporablja?
The European Medicines Agency concluded that Zyclara 3.75% cream has been shown to be effective at clearing actinic keratosis from the skin and that its use did not raise significant safety concerns.
Evropska agencija za zdravila je zaključila, da se je zdravilo Zyclara 3,75 % krema izkazala za učinkovito pri odstranjevanju aktiničnih keratoz s kože in da njena uporaba ni sprožila večjih pomislekov glede varnosti.
Actinic keratosis is a precancerous, abnormal skin growth that develops after too much exposure to sunlight.
Aktinična keratoza je predrakava, nenormalna kožna tvorba, ki se razvije ob preveliki izpostavljenosti sončni svetlobi.
If actinic keratosis is cleared after two 2-week courses but then it comes back, it can be treated again with one or two 2-week treatment courses provided these are given after a break of at least 12 weeks from the original treatment.
Če aktinična keratoza izgine po dveh dvotedenskih zdravljenjih, nato pa se znova pojavi, se lahko dvotedensko zdravljenje ponovi enkrat ali dvakrat, če je od prvotnega zdravljenja minilo vsaj 12 tednov.
The Agency therefore decided that Zyclara's benefits are greater than its risks and recommended that it be given marketing authorisation.
Agencija je zato zaključila, da so koristi zdravila Zyclara večje od z njim povezanih tveganj, in priporočila, da se zanj izda dovoljenje za promet.
Zyclara has been shown to be effective in clearing actinic keratosis from the skin in two main studies involving 479 patients with actinic keratosis on the face and scalp.
Zdravilo Zyclara se je izkazalo za učinkovito pri odstranjevanju aktiničnih keratoz s kože v dveh glavnih študijah, ki sta vključevali 479 bolnikov z aktinično keratozo na obrazu in lasišču.
The patient's response to treatment should be evaluated 8 weeks after the end of treatment, and a third 2-week course may be considered if needed.
Bolnikov odziv na zdravljenje je treba oceniti osem tednov po koncu zdravljenja, po tem pa se presodi, ali je potrebno tretje dvotedensko zdravljenje.
Zyclara is used to treat adults whose immune system (the body's natural defences) is working normally when other skin treatments for actinic keratosis cannot be used or are less appropriate.
Zdravilo Zyclara se uporablja za zdravljenje odraslih, pri katerih imunski sistem (naravni obrambni mehanizem telesa) deluje normalno in kadar drugačno zdravljenje aktiničnih keratoz ni mogoče ali je manj primerno.
Why is Zyclara approved?
Zakaj je bilo zdravilo Zyclara odobreno?
The reference medicine for Zyclara is Aldara, which contains imiquimod at 5% strength.
Referenčno zdravilo za zdravilo Zyclara je zdravilo Aldara, ki vsebuje imikvimod z jakostjo 5 %.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Zyclara have been included in the summary of product characteristics and the package leaflet.
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Zyclara upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
The cream should remain on the skin overnight (for about 8 hours) before being washed off. Daily treatment should continue for 2 weeks.
Krema mora ostati na koži čez noč (približno osem ur), preden se spere.
It contains the active substance imiquimod at 3.75% strength (100 mg cream contains 3.75 mg imiquimod).
Zdravilo vsebuje zdravilno učinkovino imikvimod z jakostjo 3,75 % (100 mg kreme vsebuje 3,75 mg imikvimoda).
It is not intended to provide practical advice on how to use Zyclara.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
What are the risks associated with Zyclara?
Kakšna tveganja so povezana z zdravilom Zyclara?
One or two sachets of Zyclara are applied in a thin layer to the affected areas of the face or balding scalp once a day before bedtime.
Ena ali dve vrečici zdravila Zyclara se naneseta v tanki plasti na prizadeto področje na obrazu ali neporaščenih delih lasišča enkrat dnevno pred spanjem.
These substances help to kill the abnormal cells in the skin that lead to keratosis.
Te snovi pomagajo uničiti nenormalne celice v koži, ki se lahko razvijejo v keratozo.
This means that it uses the immune system to bring about its effect.
To pomeni, da učinek doseže z delovanjem na imunski sistem.
The active substance in Zyclara cream, imiquimod, is an immune response modifier.
Zdravilna učinkovina v zdravilu Zyclara krema, imikvimod, je modifikator imunskega odziva.
About 11% of patients in studies with Zyclara required treatment to be interrupted due to this kind of side effect on the skin.
Približno 11 % bolnikov, ki so sodelovali v študijah z zdravilom Zyclara, se je moralo zaradi teh neželenih učinkov na koži prenehati zdraviti.
For more information about treatment with Zyclara, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Zyclara preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Treatment with Zyclara has the advantage of being easier to adhere to than Aldara treatment because it has a simpler dosing regimen.
Prednost uporabe zdravila Zyclara je v tem, da je lažje upoštevati režim zdravljenja kot pri zdravilu Aldara, saj je način odmerjanja preprostejši.
For practical information about using Zyclara, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Zyclara naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Zyclara is available as a 3.75% cream in individual sachets.
Zdravilo Zyclara je na voljo v obliki kreme z jakostjo 3,75 % v posamičnih vrečicah.
Two doses of Zyclara (2.5% and 3.75%) were compared with placebo (a dummy treatment) in these studies, and the main measure of effectiveness was the number of patients whose skin was completely cleared of the actinic keratosis after treatment.
V teh študijah so dva odmerka zdravila Zyclara (2,5 % in 3,75 %) primerjali s placebom (zdravilom brez zdravilne učinkovine), pri čemer je bilo glavno merilo učinkovitosti število bolnikov, pri katerih so bile aktinične keratoze po zdravljenju popolnoma odstranjene.
Most patients using Zyclara experience side effects on the skin where the medicine was applied (most commonly redness, scab formation, dryness and shedding of the skin).
Večina bolnikov, ki so uporabljali zdravilo Zyclara, je imela neželene učinke na koži na mestu nanosa zdravila (najpogosteje pordelost kože, nastanek krast, suha koža in luščenje kože).
Zyclara at a lower strength (2.5%) had a lower clearance rate than the 3.75% strength.
Pri uporabi zdravila Zyclara z manjšo jakostjo (2,5 %) je bila stopnja odstranitve nižja kot pri 3,75-odstotni jakosti.
How does Zyclara work?
Kako zdravilo Zyclara deluje?
Zyclara is a cream used to treat actinic keratosis on the face and balding parts of the scalp.
Zdravilo Zyclara je krema, ki se uporablja za zdravljenje aktiničnih keratoz na obrazu in neporaščenih delih lasišča.
For the full list of side effects and restrictions with Zyclara, see the package leaflet.
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Zyclara glejte navodilo za uporabo.
Around 36% of patients treated with Zyclara 3.75% cream in the two studies had complete clearance compared with around 6% of patients treated with placebo.
Stopnja popolne odstranitve je bila okoli 36 % pri bolnikih, ki so se zdravili z zdravilom Zyclara 3,75 % v obliki kreme, v primerjavi s približno 6 % pri bolnikih, ki so prejemali placebo.
How is Zyclara used?
Kako se zdravilo Zyclara uporablja?
These could be signs of a severe allergic reaction
To so lahko znaki hude alergijske reakcije.
• think you may be pregnant
• mislite, da bi lahko bili noseči
Millmount Healthcare Limited Block 7, City North Business Campus, Stamullen Co. Meath, K32 YD60 Ireland
Millmount Healthcare Limited Block 7, City North Business Campus, Stamullen Co. Meath, K32 YD60 Irska
The protein part is very similar to a natural protein produced by your own body.
Beljakovinski del je zelo podoben naravni beljakovini, ki nastaja v telesu.
MARKETING AUTHORISATION NUMBER(S) EU/1/18/1303/001
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/18/1303/001
OTHER SPECIAL WARNING(S), IF NECESSARY Avoid vigorous shaking.
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA Izogibajte se močnemu stresanju.
Your doctor will tell you what you can take to ease the bone pain
Zdravnik vam bo povedal, kaj lahko vzamete za lajšanje bolečin v kosteh.